Court Grants Natera's Request to Include Additional Patent in its Lawsuit Against NeoGenomicsBusiness Wire • 12/17/24
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon CancerBusiness Wire • 12/12/24
Clinical Validation Study on Natera's Fetal RhD NIPT Published in Obstetrics & GynecologyBusiness Wire • 12/02/24
Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant RecipientsBusiness Wire • 11/27/24
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer SymposiumBusiness Wire • 11/26/24
Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™PRNewsWire • 11/25/24
Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the YearBusiness Wire • 11/25/24
Natera (NTRA) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 11/13/24
Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal CancerBusiness Wire • 11/12/24
All You Need to Know About Natera (NTRA) Rating Upgrade to Strong BuyZacks Investment Research • 10/23/24
Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New PhaseBusiness Wire • 09/23/24
Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMOBusiness Wire • 09/16/24
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall SurvivalBusiness Wire • 09/14/24